Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Point Biopharma Global Inc
(NQ:
PNT
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 26, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Point Biopharma Global Inc
< Previous
1
2
3
4
Next >
PNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of POINT Biopharma Global, Inc. Is Fair to Shareholders
October 03, 2023
From
Halper Sadeh LLC
Via
Business Wire
A Look Into Healthcare Sector Value Stocks
October 02, 2023
Via
Benzinga
5 Value Stocks In The Healthcare Sector
September 11, 2023
Via
Benzinga
5 Value Stocks To Watch In The Healthcare Sector
September 04, 2023
Via
Benzinga
Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark
May 19, 2023
One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday.
Via
Investor's Business Daily
Why Shares of Point Biopharma Global Rose Monday
May 15, 2023
The company made a deal to help speed its clinical trials along.
Via
The Motley Fool
Earnings Preview: POINT Biopharma Global
March 23, 2023
Via
Benzinga
Arlo Technologies, Array Technologies, AirSculpt Technologies And Other Big Stocks Moving Higher On Friday
May 12, 2023
U.S. stocks traded slightly lower, with the Dow Jones dropping around 15 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
7 Biotech Stocks With Huge Return Potential for Long-Term Investors
April 26, 2023
Although a wildly speculative sector, the low-cost, high-potential biotech stocks to buy and hold may deliver the goods for gamblers.
Via
InvestorPlace
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
April 24, 2023
From
Lantheus Holdings, Inc.; POINT Biopharma Global Inc.
Via
GlobeNewswire
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
April 05, 2023
Amid the noise of the global markets recently, these speculative biotech stocks to buy might trade with a mind of their own.
Via
InvestorPlace
Earnings Scheduled For March 24, 2023
March 24, 2023
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely to report earnings for its fourth quarter. • Caledonia Mining (AMEX:CMCL) is projected to report earnings for its fourth...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2022
November 30, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
December 14, 2022
Via
Benzinga
Over $16 Million Bet On Energy Transfer? Check Out These 3 Stocks Insiders Are Buying
November 29, 2022
Although US stocks closed lower on Monday, there were a few notable insider trades.
Via
Benzinga
Analyst Ratings for POINT Biopharma Global
November 15, 2022
Over the past 3 months, 5 analysts have published their opinion on POINT Biopharma Global (NASDAQ:PNT) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
November 15, 2022
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus...
Via
Benzinga
Dow Surges 150 Points; Crude Oil Falls Sharply
November 14, 2022
U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones gaining around 150 points on Monday.
Via
Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
November 14, 2022
Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target.
Via
Benzinga
Lantheus-POINT Biopharma Ink Strategic Collaboration For Cancer Programs
November 14, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
November 14, 2022
Gainers
Via
Benzinga
Stocks Cool Off From Last Week's Rally
November 14, 2022
Stocks are starting the week off lower, unable to build off of last week's impressive rally.
Via
Talk Markets
Silver Rises Over 1%; Tyson Foods Posts Downbeat Earnings
November 14, 2022
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite dropping around 60 points on Monday.
Via
Benzinga
Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday
November 14, 2022
U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
US Stocks Mostly Lower; Nasdaq Drops Over 100 Points
November 14, 2022
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping more than 100 points on Monday.
Via
Benzinga
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
November 14, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
September 27, 2022
Gainers Benitec Biopharma (NASDAQ:BNTC) shares increased by 9.8% to $0.35 during Tuesday's after-market session. The company's market cap stands at $9.0 million.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022
September 16, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Upgrades
Via
Benzinga
Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday
September 15, 2022
Gainers AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.